Uptal D. Patel

机构：Biogen (United States), Duke University, VistaGen Therapeutics (United States), Duke Medical Center · ORCID：0000-0002-6905-6649

发表论文 243 篇 · 总被引 13872 次 · h-index 56

代表论文

• A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection (2024 · New England Journal of Medicine · 被引 170)
• Effect of felzartamab on the molecular phenotype of antibody-mediated rejection in kidney transplant biopsies (2025 · Nature Medicine · 被引 41)
• Phase 1b/2a Study Assessing the Safety and Efficacy of Felzartamab in Anti-Phospholipase A2 Receptor Autoantibody–Positive Primary Membranous Nephropathy (2024 · Kidney International Reports · 被引 28)
• Randomized, double-blind, placebo-controlled phase 2a study assessing the efficacy and safety of felzartamab for IgA nephropathy (2025 · Kidney International · 被引 23)
• Selonsertib in Patients with Diabetic Kidney Disease (2024 · Journal of the American Society of Nephrology · 被引 19)
• #425 Felzartamab (anti-CD38) in patients with IgA Nephropathy—interim results from the IGNAZ study (2024 · Nephrology Dialysis Transplantation · 被引 13)